Shares of Amgen are rallying $1.54, or 4.3 percent, to $37 in pre-open trading after the U.S. Food and Drug Administration approved the biotech firm's Aranesp for the treatment of chemotherapy-induced ...

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...

NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...

(AP) — Shares of Amgen Inc. fell Thursday over concerns that the Food and Drug Administration's plan to re-examine the safety of anemia drugs could pressure sales of leading anemia treatments Aranesp ...

BOSTON, Feb 22 (Reuters) - Amgen Inc. said on Thursday its anemia drug Aranesp has been removed from a list used by insurance companies to determine whether a drug should be reimbursed for a condition ...

A federal judge has denied a request by Johnson & Johnson to temporarily stop Amgen Inc. from selling its anemia drug Aranesp at a discount to doctors who agree to also buy another Amgen product, the ...

Amgen Inc., the world’s largest biotechnology company, said Thursday that earnings rose 6.2% for the second quarter on higher sales of its blockbuster drugs, Epogen and Neupogen. The company reported ...

Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. The Thousand Oaks, Calif., company pleaded ...

SAN FRANCISCO (MarketWatch) -- Amgen Inc. late Monday reported a 14% rise in third-quarter profit that was powered by a surge in sales of the biotechnology company's lead product, the anemia treatment ...

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

Biologic drugmaker Amgen said Tuesday that it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall ...